<SEC-DOCUMENT>0001554855-26-000915.txt : 20260506
<SEC-HEADER>0001554855-26-000915.hdr.sgml : 20260506
<ACCEPTANCE-DATETIME>20260506171156
ACCESSION NUMBER:		0001554855-26-000915
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20260506
FILED AS OF DATE:		20260506
DATE AS OF CHANGE:		20260506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRINITY BIOTECH PLC
		CENTRAL INDEX KEY:			0000888721
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22320
		FILM NUMBER:		26949659

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		IDA BUSINESS PARK
		STREET 2:		BRAY
		CITY:			WICKLOW
		PROVINCE COUNTRY:   	L2
		BUSINESS PHONE:		01135312955111

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		IDA BUSINESS PARK
		STREET 2:		BRAY
		CITY:			WICKLOW
		PROVINCE COUNTRY:   	L2
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>MainDocument.htm
<DESCRIPTION>6-K
<TEXT>
<html><head><title></title><meta content="text/html"></meta></head><body style="font-family:'Times New Roman'; font-size:12pt; background:#ffffff"><div class="content_container"><div class="Section_1"><div style="margin:0.1pt"><table cellspacing="0" cellpadding="0" style="width:100%; -aw-border-insideh:0.5pt single #000000; -aw-border-insidev:0.5pt single #000000; border-collapse:collapse"><tr style="height:10.8pt;"><td style="width:539.5pt; border-top:3pt solid #000000; border-bottom:0.75pt solid #000000; vertical-align:top; -aw-border-bottom:0.5pt single"><p style="margin-top:0pt; margin-bottom:0pt; line-height:12pt"><font style="font-size:1pt;">&#160;</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center"><font style="font-weight:bold">SECURITIES AND EXCHANGE COMMISSION</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">Washington, D.C.</font><font style="font-weight:bold">&#160;</font><font style="font-weight:bold"> 20549</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><img src="cfee00b162c23b7248d7.jpg" alt="Graphics" style="height:2; width:156;"></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">F O R M</font><font style="font-weight:bold">&#160;</font><font style="font-weight:bold">6-K</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">For the month of May 2026</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">TRINITY BIOTECH PLC</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>(Name of Registrant)</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>IDA Business Park</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>Bray, Co. Wicklow, Ireland</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>(Address of Principal Executive Office)</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold;">&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">Form 20-F </font><font style="font-family:'Segoe UI Symbol'; font-weight:bold">&#9746;</font><font style="font-weight:bold">&#160;</font><font style="font-weight:bold">&#160;</font><font style="font-weight:bold">&#160;</font><font style="font-weight:bold"> Form 40-F </font><font style="font-family:'Segoe UI Symbol'; font-weight:bold">&#9744;</font></p><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font style="font-weight:bold;">&#160;</font></p><p style="margin-top:0pt; margin-right:0.1pt; margin-bottom:0pt; font-size:10pt"><font style="font-weight:bold">This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).</font></p><p style="margin-top:0pt; margin-right:0.1pt; margin-bottom:0pt; font-size:10pt"><font style="font-weight:bold;">&#160;</font></p><div style="-aw-sdt-tag:'PG_c4a37b9e994ac9da'"><div align="center" style="margin-right:0.1pt"><hr size="1" align="center" style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div></div><div class="Section_2"><div style="margin:0.1pt"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">EXPLANATORY NOTE</font></p><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p><div style="margin-top:10pt; margin-bottom:10pt"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>On May 1, 2026, the Company issued a press release announcing the appointment of Jerry Lydon as Head of North America Commercial Operations. The Company also provided an update on progress under its Comprehensive Transformation Plan and reported selected financial results for the quarter and year ended December 31, 2025. A copy of the press release is filed herewith as Exhibit 99.1.</font></p><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p><div style="-aw-sdt-tag:'PG_72917bc263ce5510'"><div align="center" style="margin-right:0.1pt"><hr size="1" align="center" style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div></div></div><div class="Section_3"><div style="margin:0.1pt"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; widows:0; orphans:0; font-size:10pt"><font style="font-weight:bold">EXHIBIT INDEX</font></p><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="width:6.52%; border-bottom:1pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>Exhibit</font></p></td><td style="width:0.54%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:92.94%; border-bottom:1pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; widows:0; orphans:0; font-size:10pt"><font>Description</font></p></td></tr><tr><td style="width:6.52%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0"><font><font style="font-size: 10pt;">99.1</font></font></p><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:0.54%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0"><font><br></font><font style="font-size:10pt;">&#160;</font></p></td><td style="width:92.94%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; widows:0; orphans:0"><a href="ex991_1.htm" style="-sec-extract:exhibit"><font style="font-size:10pt; text-decoration:underline; color:#0000ff">Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations</font></a></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><div style="-aw-sdt-tag:'PG_1f2a2651d98fd6f4'"><div align="center" style="margin-right:0.1pt"><hr size="1" align="center" style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div></div><div class="Section_4"><div style="margin:0.1pt"><p style="margin:0pt 0.2pt; text-align:center; widows:0; orphans:0; font-size:10pt"><font>SIGNATURES</font></p><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-indent:36pt; text-align:justify; widows:0; orphans:0; font-size:10pt"><font>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="width:49.82%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td colspan="2" style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; widows:0; orphans:0; font-size:10pt"><font style="text-decoration:underline">TRINITY BIOTECH PLC</font></p></td><td style="width:18%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="width:49.82%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:29.4%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; widows:0; orphans:0; font-size:10pt"><font>Trinity Biotech plc</font></p></td><td style="width:18%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="width:49.82%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:29.4%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; widows:0; orphans:0; font-size:10pt"><font>(Registrant)</font></p></td><td style="width:18%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="width:49.82%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:29.4%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:18%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="width:49.82%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; widows:0; orphans:0; font-size:10pt"><font>By:</font></p></td><td style="width:29.4%; border-bottom:1pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; widows:0; orphans:0; font-size:10pt"><font>/s/ Paul Murphy</font></p></td><td style="width:18%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="width:49.82%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:29.4%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; widows:0; orphans:0; font-size:10pt"><font>Paul Murphy</font></p></td><td style="width:18%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="width:49.82%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td><td style="width:29.4%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; widows:0; orphans:0; font-size:10pt"><font>Interim Chief Financial Officer</font></p></td><td style="width:18%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; widows:0; orphans:0; font-size:10pt"><font>Date:</font><font>&#160;</font><font> </font><font>&#160;</font><font>May 6, 2026</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p><div style="-aw-sdt-tag:'PG_2d61b696d77151e2'"><div align="center"><hr size="1" align="center" style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head><title></title><meta content="text/html"></meta></head><body style="font-family:'Times New Roman'; font-size:12pt; background:#ffffff"><div class="content_container"><div class="Section_1"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tr><td style="width:528.7pt; border-top:0.75pt solid #000000; border-bottom:3pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; widows:0; orphans:0; font-size:7.5pt"><a name="EXH_69fb013361f5952738d11a76" href="#"></a><font>&#160;</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; widows:0; orphans:0; font-size:10pt"><font style="font-weight:bold; text-decoration:underline; background-color:#ffffff">Exhibit 99.1</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; widows:0; orphans:0; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font style="color:#ee0000;">&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tr><td style="width:259.2pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="width:259.2pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:0pt; margin-left:71.1pt; margin-bottom:0pt; font-size:10pt"><img src="ca9c95bf97e1c8478b7d.jpg" alt="Graphics" style="margin-right:9pt; margin-left:9pt; float:right; position:relative; height:61; width:228;"></p><p style="margin-top:0pt; margin-left:71.1pt; margin-bottom:0pt; font-size:10pt"><font style="font-weight:bold;">&#160;</font></p></td></tr><tr><td style="width:259.2pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>Contact:</font><font>&#160;&#160; </font><font style="font-weight:bold">Trinity Biotech plc</font></p><p style="margin-top:0pt; margin-left:35.1pt; margin-bottom:0pt; font-size:10pt"><font>&#160;&#160; </font><font>Paul Murphy</font></p><p style="margin-top:0pt; margin-left:39.6pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font><font>(353)-1-2769800</font></p></td><td style="width:259.2pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle"><p style="margin-top:0pt; margin-left:57.6pt; margin-bottom:0pt; font-size:10pt"><font style="font-weight:bold;">&#160;</font></p><p style="margin-top:0pt; margin-left:57.6pt; margin-bottom:0pt; font-size:10pt"><font style="font-weight:bold">RedChip Companies Inc.</font></p><p style="margin-top:0pt; margin-left:57.6pt; margin-bottom:0pt; font-size:10pt"><font>Dave Gentry, CEO</font></p><p style="margin-top:0pt; margin-left:57.6pt; margin-bottom:0pt; font-size:10pt"><font>(1)-407-644-4256</font></p><p style="margin-top:0pt; margin-left:57.6pt; margin-bottom:0pt; font-size:10pt"><font>(1)-800-RED-CHIP (733-2447)</font></p><p style="margin-top:0pt; margin-left:57.6pt; margin-bottom:0pt; font-size:10pt"><font>TRIB@redchip.com</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font style="color:#ee0000;">&#160;</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center"><font style="font-weight:bold">Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold; color:#003366;">&#160;</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; text-align:center; line-height:116%; font-size:10pt;"><font><font style="font-weight:bold">-</font><font style="width:14.67pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; line-height:116%; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:40.5pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-weight:bold">-</font><font style="width:14.67pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Company announces further operational progress in its Comprehensive Transformation Plan</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; line-height:116%; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:45pt; margin-bottom:8pt; text-indent:-18pt; text-align:center; line-height:116%; font-size:10pt;"><font><font style="font-weight:bold">-</font><font style="width:14.67pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Company publishes Q4, 2025 financial results with revenue broadly in line with previously issued trading update &amp; year-on-year gross margin percentage improvements</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold; color:#003366;">&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font style="font-weight:bold">DUBLIN, Ireland (May 01, 2026) -</font><font>&#160;</font><font>Trinity Biotech plc (NASDAQ: TRIB) (&#8220;Trinity&#8221; or the &#8220;Company&#8221;), a commercial&#8209;stage diagnostics and health technology company, today announced the appointment of Jerry Lydon as Head of North America Commercial Operations.</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Mr. Lydon&#8217;s appointment represents a deliberate next step as the Company&#8217;s core diagnostics business transitions from the execution phase of its Comprehensive Transformation Plan toward a sustained focus on building revenue momentum and, importantly, driving profitability from a more efficient and disciplined operating base.</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>The appointment also aligns with recent upgrades to the Company&#8217;s Premier HbA1c 9210&#8482; platform, the Company&#8217;s laboratory blood glucose monitoring solution. The enhanced Premier Hb9210&#8482; platform recently became the only HbA1c system worldwide to receive the prestigious International Federation of Clinical Chemistry &#8220;Gold&#8221; classification for 2026, a designation recognising the highest levels of clinical accuracy, precision and traceability. </font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Over the past two years, Trinity has implemented a wide&#8209;ranging transformation program designed to simplify its operating footprint, improve cost control, rationalise manufacturing, and prioritise profitability. With many of these foundational actions substantially completed, management is now focused on extracting greater operating leverage and financial returns from that improved structure, including across the North America business.</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Jerry Lydon brings extensive commercial leadership experience in diagnostics and healthcare, with a strong track record of improving sales execution, managing distributor and direct sales channels. In his role, Mr. Lydon will oversee Trinity&#8217;s North America commercial organisation, with responsibility for commercial execution across the core diagnostics portfolio.</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>As part of this role, Mr. Lydon will lead commercial operations for the Company&#8217;s New York State Department of Health-approved reference laboratory, including supporting the commercialisation planning for a pipeline of new products in development, such as:</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:36.75pt; margin-bottom:0pt; text-indent:-18pt; text-align:justify; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>EpiCapture, a proprietary epigenetic assay for prostate cancer monitoring, and</font></p><p style="margin-top:0pt; margin-left:36.75pt; margin-bottom:0pt; text-indent:-18pt; text-align:justify; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>PrePsia, a proprietary early-pregnancy blood test to assess risk of developing preeclampsia, a serious pregnancy complication.. </font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Commenting on the appointment, John Gillard, President &amp; Chief Executive Officer of Trinity Biotech, said:</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#8220;Jerry&#8217;s appointment reflects our focus on strengthening execution and improving the quality and profitability of revenue in North America. Following an intensive transformation program, our priority in our core diagnostics business is to generate sustainable financial improvement from the operating base we have put in place. Jerry&#8217;s experience will be important both in advancing key products such as the upgraded Premier HbA1c 9210 and in supporting the commercial readiness of our NYSDOH&#8209;approved reference lab and its development pipeline.</font><font>&#160; </font><font>It is a timely appointment in terms of supporting and strengthening the core business while we continue to drive our broader innovation agenda.&#8221;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Mr. Lydon added:</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#8220;The Company has made important changes to its operating and cost structure, while selectively investing in product upgrades and introductions. My focus is on disciplined commercial execution - supporting customers, strengthening channels, and ensuring that revenue growth is aligned with profitability and operational performance.&#8221;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:0.75pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><div style="-aw-sdt-tag:'PG_68f9c72204e37243'"><div align="center"><hr size="1" align="center" style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_2"><p style="margin-top:14pt; margin-bottom:14pt; text-align:justify; font-size:10pt"><font style="font-weight:bold">Continued Progress Across the Comprehensive Transformation Plan</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>The Company also highlighted continued progress across key elements of its transformation plan, with several initiatives now moving from implementation to financial contribution:</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>TrinScreen&#8482; HIV manufacturing under the outsourced operating model has been successfully scaled, recently reaching targeted production levels by early Q2 2026.</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:8pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Uni&#8209;Gold&#8482; HIV manufacturing under the outsourced structure commenced during Q2 2026 and is currently being scaled following regulatory approval received in early 2026.</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>Both initiatives are expected to support revenue and profitability from Q2 2026 onwards, reflecting the benefits of a more variable cost structure, improved gross margins, and reduced operational complexity.</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font style="font-weight:bold">Q4 2025 Results</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Revenues for Q4 2025 were $11.1m which is broadly in-line with the Company&#8217;s guidance issued as part of its March 10, 2026 Business and Trading Update.</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>This compares to Q4, 2024 revenue of $15.9 million, which was driven by a substantial increase in TrinScreen&#8482; HIV sales from $0.4 million in Q4, 2023 to $3.2 million in Q4, 2024.</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>The reduction in revenue between Q4, 2024 and Q4, 2025 was primarily driven by:</font></p><p style="margin-top:0pt; margin-left:72pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:'Courier New'">o</font><font style="width:12pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>The residual impact of the disruption to the global health market for HIV testing in 2025 due to changes affecting international aid funding structures, and</font></p><p style="margin-top:0pt; margin-left:72pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:'Courier New'">o</font><font style="width:12pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>The fine-tuning of manufacturing and supply-chain processes to accommodate the rise in demand for TrinScreen&#8482; HIV in late 2025 as the Company transitioned to outsourced manufacturing under the Company&#8217;s Comprehensive Transformation Plan &#8211; as referenced above this has now been successfully scaled up.</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Gross margin increased over 400 basis points from 30.8% to 35.2% supported by changes to the Company&#8217;s operating structure under its Comprehensive Transformation Plan. </font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Gross profit for Q4 2025 was $3.9m compared to $4.9m in Q4 2024 driven by lower sales, partially offset by the higher gross margin percentage. </font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Net Loss of $17.5m (Q4 2024: net loss of $17.0m) which included a one&#8209;off IFRS-driven charge of $10.0m associated with the modification of the Perceptive financing arrangements in December 2025.</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Adjusted EBITDA</font><font style="line-height:116%; font-size:6.67pt; vertical-align:super">1</font><font> of negative $0.5m for Q4 2025 compared to negative $7.0m for Q4 2024.</font></p><p style="margin-top:0pt; margin-bottom:0pt; line-height:116%; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font style="font-weight:bold">Year ended December 31, 2025</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Revenues for 2025 of $43.8m compared to $61.6m in Q4 2024:</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>The reduction in revenue between 2024 and 2025 was primarily driven by:</font></p><p style="margin-top:0pt; margin-left:72pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:'Courier New'">o</font><font style="width:12pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Point&#8209;of&#8209;care revenues declined to $8.1m in 2025 (2024: $17.4m), primarily driven by reductions in HIV sales as a result of disruption to the international funding landscape for global health Rapid HIV testing in the earlier part of 2025, and the fine-tuning of manufacturing and supply-chain processes to accommodate the rise in demand for TrinScreen</font><font style="line-height:116%; font-size:6pt; vertical-align:super">TM</font><font> HIV in late 2025.</font></p><p style="margin-top:0pt; margin-left:72pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:'Courier New'">o</font><font style="width:12pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Haemoglobin revenues decreased to $16.9m in 2025 (2024: $20.1m) partly driven by temporary manufacturing disruption during the planned transition of production under the Group&#8217;s Comprehensive Transformation Plan.</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Gross profit was $16.9m in 2025 (2024: $21.4m), with gross margin increasing almost 400 basis points from 34.8% to 38.6%, reflecting benefits from the Group&#8217;s Comprehensive Transformation Plan, including manufacturing consolidation and improved operating efficiency. </font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Net Loss of $37.4m (2024: net loss of $31.8m) which included a one&#8209;off IFRS-driven charge of $10.0m associated with the modification of the Perceptive financing arrangements in December 2025.</font></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:8pt; text-indent:-18pt; line-height:116%; font-size:10pt;"><font><font style="font-family:Symbol">&#61623;</font><font style="width:13.4pt; font:7pt 'Times New Roman'; display:inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font><font>Adjusted EBITDA of negative $5.9m for 2025 compared to negative $11.3m for 2024.</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>The Company has issued a full presentation of its Q4 2025 and year ended December 31, 2025 results which can be viewed on the Company&#8217;s website www.trinitybiotech.com/investor-relations/financial-reports.</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt"><font style="font-size:6pt; vertical-align:super">1 </font><font>Earnings before interest, tax, depreciation, amortisation, and share-based compensation charges &#8211; also excludes impairment charges, restructuring &amp; transformation costs and non-recurring corporate finance and transaction-related costs.</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><div style="-aw-sdt-tag:'PG_e7a4c27034c1c8b9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><div align="center"><hr size="1" align="center" style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_3"><p style="margin-top:14pt; margin-bottom:14pt; text-align:justify; font-size:10pt"><font style="font-weight:bold">Forward-Looking Statements</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>This release includes statements that constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (the &#8220;Reform Act&#8221;), including but not limited to statements related to Trinity Biotech&#8217;s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms &#8220;may,&#8221; &#8220;believes,&#8221; &#8220;projects,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to reduce our debt and improve our capitalization, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company&#8217;s distributors, losses or system failures with respect to Trinity Biotech&#8217;s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech&#8217;s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech&#8217;s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under &#8220;Risk Factors&#8221; in Trinity Biotech&#8217;s annual report on Form 20-F for the fiscal year ended December 31, 2025 and Trinity Biotech&#8217;s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.</font></p><p style="margin-top:14pt; margin-bottom:14pt; font-size:10pt"><font style="font-weight:bold">Use of Non-IFRS Financial Measures</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>The Company&#8217;s unaudited financial statements were prepared in accordance with International Financial Reporting Standards</font><font>&#160;</font><font>(IFRS). To supplement the consolidated financial statements presented in accordance with IFRS, the Company presents non-IFRS presentations of EBITDA and Adjusted EBITDA. The adjustments to the Company's IFRS results are made with the intent of providing both management and investors a more complete understanding of the Company's underlying operational results, trends, and performance. Non-IFRS financial measures mainly exclude, if and when applicable, the effect of share-based compensation charges, depreciation, amortization and impairment charges.</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><font style="font-size:10pt">EBITDA and Adjusted EBITDA is presented to evaluate the Company's financial and operating results on a consistent basis from period to period. The Company also believes that these measures, when viewed in combination with the Company's financial results prepared in accordance with IFRS, provides useful information to investors to evaluate ongoing operating results and trends. EBITDA and Adjusted EBITDA, however, should not be considered as an alternative to operating income or net income for the period and may not be indicative of the historic operating results of the Company; nor is it meant to be predictive of potential future results. EBITDA and Adjusted EBITDA are not measures of financial performance under IFRS and may not be comparable to other similarly titled measures for other companies. Reconciliation between the Company's operating profit/(loss) and EBITDA and Adjusted EBITDA are presented with the Company&#8217;s financial results available on the Company&#8217;s website, </font><font><font style="font-size: 10pt;">www.trinitybiotech.com/investor-relations/financial-reports</font></font><font style="font-size:10pt">.</font></p><p style="margin-top:14pt; margin-bottom:14pt; text-align:justify; font-size:10pt"><font style="font-weight:bold">About Trinity Biotech</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tr><td style="width:528.7pt; border-top:0.75pt solid #000000; border-bottom:3pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:7.5pt"><font>&#160;</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt"><font>&#160;</font></p></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cfee00b162c23b7248d7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cfee00b162c23b7248d7.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  $ 44# 2(  A$! Q$!_\0
M%0 ! 0                    O_Q  4$ $                     _\0
M% $!                     /_$ !01 0                    #_V@ ,
M P$  A$#$0 _ )_X                                         /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ca9c95bf97e1c8478b7d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ca9c95bf97e1c8478b7d.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "  =L# 2(  A$! Q$!_\0
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MII2FFFFE*::::4IIIII2GC6DD8!S@#D^V<?P^G^?MK9<7VJ/)P 20"?"1R<
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M-<6DA3ICL.):3\,.+;+B.[MCL2)<AJ+$97(DR%!MEEI)6ZM:B G:E()('E6
M>/@9K&F3(L",_,FR&HL6.VIU^0\H(::;2 5+6M2DI3QPG*@"2/M7VNHCJ4VA
MZ7]OY^Y.\-WTVT[?B-K$8R5NNU"JS V5HATNFQ6WYE0>[ 5*0S'=+22%K"!E
M0@Z]0GJ&-^I9U04*WM[K^N#;+H]H-6J52IED4F)453KCC4Y*DTF-4J90(DNJ
M5*LU]QIEIIB2](:AF;)[G8A0G%GWJ!^H;N_U];GN7'>,^;1-OK?GU%W;S;V
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M;CWY_CG\SY.YGQ^/C6VU_P!M.,8Q[?F?IK4H@843@#/L3Y'X>/SUXN P !X
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M;"I<<+<6$MDN8"E8.NZ-'D3'TQHD=^5(7G8S':6\ZO:DK5M;;"EJPD%1PDX
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MQN\C)!&<YK"U2HCJWTH\_P#1MU^?/T+H!SSD^?D\D^]9"?M(  Z)*.G]X)W
MIX(/@GX3O)^O\C7='H$-MN^G7MW\1M"NVMUH#*$DA)9@?+DCNP   #X']W2W
MVD!:5=$M((\JO^ X ?(2&G <\XS^1(_'V/=?H"$?\.K;HCD*KE;PH X/:U3P
M< @*_M#GM XP3D#/4Z1_@=85G!.JCM5NP<EEWD'(P>4?!\5E1A_GVEYX T<T
MK!('/<9P?N<9QYXR1692MT2G5FDU"DSXL9^%4X4N%)9=:0M+C4EDM*3VD $
M+SR?(&H 4:W9_IN>L33H$EV31[,;W4J)ILE@*CQW[,O5^4:>SV]Q0XQ%_:=-
M2H9*4_#! Q@#T%%J!0HY4 !SC@CN.$J^H!Q_ C('&HLOVC_I.G7#M_8/5A9C
M$=FM;<5)FA7@8Z71/719X;5!J*'D)2E8@SZ?361\0I<;;=*FU<%*L/IA=66;
MW*L,YTBW:GA.VMX*/H$A25"*>>"K>M>W'/<"/<<9?6:Q/2;!"U/;6DJNVC[B
MQ>(RD>E9B,N-JFH*ARI("&G"G@8:(SA1!DF7[N=0+%VJNO=>=,:-O6W9U0O!
MR47$I0_ @T=RJLJ0HY3EY"$)2?'S<\8(A)>GW:=;]1?U:[EWZNI#U3M.S+TF
MW](>F(,J/'IU D&/9]-!)",%ZGT]T)[0E*7@4@X!/;^_WJIPKV]'6P=M(E6F
MG=RZDP-I+L"'4_>6;>MAQQI=3DR 4NKC52F45ME2$E3RERPEP*;[U:R<_9TN
MG1>V7234-VJU2VHUQ;OW35)].?6V4S3;-.1!I,)EY90/E<E4F3+0VD]G:Z%9
M#A4$V*!;']!:4U9<I>YJ[3IS^F(&]!"S'&%.OH./"CG!!R>VA1\@BJ7*^,=3
M-<:&LT!??LEK@1M7W9+0RA4O8E;$-P [?Y:RE!0H9 ?4C& :D11FVD--M-MH
M;;;0$(0D?*A*$@)2GA.    !X''N=1!OM1Q[*WTI+3P1#W%[ACE24R;144IP
M#R1D >Y.,C.=2_FL^< )R2.  !CQCCG//.//X'$0'[4A@UGI2P,G[EN-C&.X
M$R+1"5#SC''T_09(K72,?Y>V@!1.&KAR,[E'\/E@<>2K>4DCW55PZY^KIAJ
M*VD8MN? 2/\ &$+&#P!C)Q6/7I-](?K6ZF-C[2WAVHW@HUO61<:5KI=&FUZK
M4^33L1H<E:!'BM.,\MR64X2I/*.-7*I] GU(1\RM_P"W@ DD*_I975?$.,!)
M3]V &3SGGD@><9S\^AYW*].K9=1RHJ:<4HK^=05^R:("KN)X3P/'(SX5[9=S
MC!(4I(QY[0M.,#P#C!\^WY'P3/ZBZI:I@7V\0F3:^U$N$IAE1MS>\MM.D#NN
M8"E[LE>Y6X@K4<@DYJFF.B>C+IIVR7!]%Y3(F6J!)D=JY*0@N.1V@0E*0YM
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ML_)(\ =Q[>/[7 *AC$Y1:AW))X )P<C))0KP,Y!Q]<#/Z:@NL7_71T@8 MD
M\#:2D)5G QD\9/CD9JT] QNZ?QTD9*KI=4'@^G*VL\'&,9(^V<<'Q V]="]F
M[S]3NT;-NJI%NR+-C[=T>:92U"'3J-/J<>H5ITI'< @QZA)6M03R%*)XU*(V
MY]27T[+$L:UK4HV_VVU*IU%HE,@-PHCSC+$=YJ*T%@]D;_NE\N*<5\V5=WDY
MS%(];*S8\GU454JY"]&MR\GMLX]1D-+*'E4>H.4NE5-3'SM_UC4=+ZCAQO(
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MWKVJ3X=C]V!(1A1)[A.<@'WQF-VT]5#;RJJ:A[F6K6K2F+::[:A366JG DO
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M6OM)](N2L4JA[1=+NY=9F5.JT^GHDU>(EL-L29C++S[4:DSZK\53<=:EI2M
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M3=)L>8T\S'BR;A;]56@I02EY26KQ<;_:V$%)#<>,TK:G=N5?@V%]OSJ"B?H
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.TTI33332E----*5__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
